FDA Grants Orphan Drug Designation to Thrombotic Thrombocytopenic Purpura Drug
GC1126A is designed to treat the rare blood disorder.
GC Biopharma Corp. announced that GC1126A has been granted orphan drug designation by FDA. This will provide certain incentives, such as tax credits for clinical development costs.
The drug is a treatment for Thrombotic Thrombocytopenic Purpura, a rare and life-threatening blood disorder that can cause the formation of small blood clots.
GC1126A is designed to evade antibodies, providing it with a longer half-life within the body.
In a press release, a spokesperson for GC Biopharma said, “We are dedicated to collecting data to develop a Best-in-Class treatment for such rare disorders. We remain committed to our mission of providing patients with new treatment options by continuously developing innovative drugs."
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Beyond the Prescription: The Role Pharma Plays in Digital Health Conversations
April 1st 2025As social media continues to influence healthcare communication, it presents both challenges and opportunities for the pharmaceutical industry. In this interview, Jennifer Harakal of Canopy Life Sciences discusses balancing compliance with effective digital engagement to build trust and facilitate meaningful healthcare conversations.
